Eli Lilly and Company (NYSE:LLY) Stock Jumps 2.5% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s stock price shot up 2.5% during trading on Wednesday. The stock traded as high as $1,206.63 and last traded at $1,186.95. Approximately 2,294,125 shares changed hands during mid-day trading, a decline of 23% from the average session volume of 2,971,630 shares. The stock had previously closed at $1,157.49.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher price target: Cantor Fitzgerald raised its target on Eli Lilly from $1,410 to $1,440 and maintained an Overweight rating, implying substantial potential upside and reinforcing bullish sentiment. Cantor Fitzgerald lifts price targets
• Positive Sentiment: Encouraging obesity and psoriasis data: Exploratory Phase 3b TOGETHER-PsO results showed broader biomarker changes when Taltz was used with Zepbound versus Taltz alone in adults with psoriasis and obesity. Although the findings are early and exploratory, they support Lilly’s strategy of combining its immunology and metabolic franchises. Lilly Taltz and Zepbound Phase 3b data
• Positive Sentiment: Long-term growth narrative remains intact: Recent investor commentary points to strong demand for Zepbound, manufacturing expansion and a broader pipeline beyond GLP-1 drugs. Lilly and Nvidia also reportedly committed up to $1 billion to an AI drug-discovery laboratory, potentially accelerating research productivity. Nvidia and Eli Lilly AI drug discovery lab
• Neutral Sentiment: Technical and investor attention: LLY recently moved above its 50-day moving average and remains one of the most-watched stocks on Zacks, which may support trading interest but does not change the company’s fundamentals. Lilly moves above its 50-day moving average
• Negative Sentiment: Large shareholder sale: Lilly’s largest shareholder filed to sell nearly $347 million of stock. The transaction may create near-term supply pressure, though it could also reflect portfolio or liquidity decisions rather than a negative view of the business. Lilly shareholder stock sale
• Negative Sentiment: Litigation over gastrointestinal problems: Lilly is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. The case adds legal and reputational risk to the company’s rapidly expanding incretin-drug franchise. Lilly lawsuit over stomach problems

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Sanford C. Bernstein lifted their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Citigroup boosted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Finally, Morgan Stanley raised their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Trading Up 0.5%

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 39.44, a P/E/G ratio of 1.46 and a beta of 0.46. The business’s 50-day simple moving average is $1,173.78 and its 200-day simple moving average is $1,096.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the company earned $6.31 EPS. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Maseco LLP boosted its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after buying an additional 27 shares during the period. Finally, Marshall & Sterling Wealth Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after buying an additional 15 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.